Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing.
AffiliationUniversity of Manchester, Central Manchester Foundation Hospital NHS Trust, St Mary's Hospital, Manchester, UK. Gareth.email@example.com
MetadataShow full item record
AbstractSelection for genetic testing of BRCA1/BRCA2 is an important area of healthcare. Although testing costs for mutational analysis are falling, costs in North America remain in excess of US$3000 (UK price can be 690 pounds). Guidelines in most countries use a 10-20% threshold of detecting a mutation in BRCA1/2 combined within a family before mutational analysis is considered. A number of computer-based models have been developed. However, use of these models can be time consuming and difficult. The Manchester scoring system was developed in 2003 to simplify the selection process without losing accuracy.
CitationAddition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. 2009, 46 (12):811-7 J Med Genet
JournalJournal of Medical Genetics